Recent

% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

zahnd9898 24 posts  |  Last Activity: 1 hour 50 minutes ago Member since: Sep 28, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Buying with big boys!

    Sentiment: Strong Buy

  • Drag on share price!
    Let him go to work for jimmy!

    Sentiment: Strong Buy

  • Reply to

    dopeydan: Basically NOT Relevant......

    by setto.plunge Jul 30, 2015 8:22 PM
    zahnd9898 zahnd9898 Jul 31, 2015 11:32 AM Flag

    YES! jimmy!!!!!!!!!!!

    Sentiment: Strong Buy

  • Reply to

    Zuplenz is launched.

    by xtraname4 Jul 29, 2015 7:11 AM
    zahnd9898 zahnd9898 Jul 29, 2015 9:32 AM Flag

    MONEY!
    Time to buy buy BUY!!!

    Sentiment: Strong Buy

  • zahnd9898 by zahnd9898 Jul 24, 2015 1:11 PM Flag

    WHY BUY! ,Jan 7, 2015 CRAMER JAMES JDirector 33,013 Direct Automatic Sale at $2.16 per share. 71,308
    Jan 6, 2015 CRAMER JAMES JDirector 33,010 Direct Automatic Sale at $2.18 per share. 71,961
    Jan 5, 2015 CRAMER JAMES JDirector 33,010 Direct Automatic Sale at $2.26 per share. 74,602
    Jan 2, 2015 FAY SARAH ANNDirector 26,906 Direct Option Exercise N/A
    Jan 2, 2015 CRAMER JAMES JDirector 33,010 Direct Automatic Sale at $2.30 per share. 75,923
    Jan 2, 2015 WALSH MARK LAWSONDirector 26,906 Direct Option Exercise N/A
    Jan 2, 2015 HALL KEITHDirector 26,906 Direct Option Exercise N/A
    Dec 31, 2014 CRAMER JAMES JDirector 175,754 Direct Disposition (Non Open Market) at $2.38 per share. 418,294
    Dec 31, 2014 CRAMER JAMES JDirector 33,010 Direct Automatic Sale at $2.36 per share. 77,903
    Dec 31, 2014 CRAMER JAMES JDirector 340,807 Direct Option Exercise at $0 per share. N/A
    Nov 7, 2014 FAY SARAH ANNDirector 11,750 Direct Purchase at $2.14 per share. 25,145
    May 22, 2014 HALL KEITHDirector 765 Direct Option Exercise at $1.61 per share. 1,231
    Apr 8, 2014 TCV VI MANAGEMENT, L.L.C.Other 5,000 Direct Sale at $2.49 per share. 12,450
    Mar 28, 2014 HALL KEITHDirector 5,000 Direct Option Exercise at $1.69 per share. 8,450
    Mar 27, 2014 TCV VI MANAGEMENT, L.L.C.Other 5,000 Indirect Disposition (Non Open Market) at $0 per share. N/A
    Mar 27, 2014 TCV VI MANAGEMENT, L.L.C.Other 5,000 Direct Acquisition (Non Open Market) at $0 per share. N/A
    Mar 27, 2014 TCV VI MANAGEMENT, L.L.C.Other 5,000 Indirect Option Exercise at $1.69 per share. 8,450
    Dec 31, 2013 CRAMER JAMES JDirector 108,336 Direct Disposition (Non Open Market) at $2.26 per share. 244,839
    Dec 31, 2013 CRAMER JAMES JDirector 210,077 Direct Acquisition (Non Open Market) at $2.26 per share.

  • zahnd9898 zahnd9898 Jul 24, 2015 1:05 PM Flag

    cramer is that you again!
    YOU SHOULD SPEND MORE TIME WITH YOUR OWN STOCK (TST) AFTER YOU TOOK YOUR INVESTORS MONEYS!

    Sentiment: Strong Buy

  • zahnd9898 by zahnd9898 Jul 17, 2015 3:14 PM Flag

    Business Summary

    Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company’s lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with Herceptin for neoadjuvantly treated node positive and negative HER2 IHC 3+ patients not achieving a pathological complete response. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials for the prevention of recurrence in patients with ovarian and endometrial cancers; and GALE-401 (anagrelide controlled release), which is in a Phase 2 clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers in India and with Teva Pharmceuticals in Israel. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in

    Sentiment: Strong Buy

  • zahnd9898 zahnd9898 Jul 17, 2015 3:11 PM Flag

    With you, I think the will jump up at the end of the day.

    Sentiment: Strong Buy

  • Reply to

    Current partners of Gale

    by orchids3333 Jul 17, 2015 12:35 PM
    zahnd9898 zahnd9898 Jul 17, 2015 2:30 PM Flag

    COULD HAVE A TAKE=OVER BY MERK!

    Sentiment: Strong Buy

  • Cnbc, yahoo the street all independent third partys!

    Sentiment: Strong Buy

  • zahnd9898 zahnd9898 Jul 17, 2015 2:04 PM Flag

    A ROLLING STONE GROWS NO MOSS!!!!!!!!!!
    MAD TRADE!

    Sentiment: Strong Buy

  • Reply to

    DO YOUR DD, HOMEWORK!

    by zahnd9898 Jul 17, 2015 9:36 AM
    zahnd9898 zahnd9898 Jul 17, 2015 9:52 AM Flag

    sHORTIE! Do your DD and COVER!

    Sentiment: Strong Buy

  • zahnd9898 by zahnd9898 Jul 17, 2015 9:36 AM Flag

    Know what you own!
    Be ready for double digit moves!
    Z!

    Sentiment: Strong Buy

  • zahnd9898 by zahnd9898 Jul 13, 2015 11:24 AM Flag

    Time to be in this market!

    Sentiment: Strong Buy

  • TIME TO BUY BUY BUY! She has legs!

    Sentiment: Strong Buy

  • Shortie hitting the door!

  • zahnd9898 by zahnd9898 Jun 11, 2015 10:58 AM Flag

    DO THE DD.

    Within the biotechnology sector there pretty much hasn't been a hotter company over the last two weeks than Galena Biopharma (NASDAQ: GALE).

    Galena, which focuses on developing cancer vaccines designed to enhance the ability of a patient's immune system to fight off the recurrence of cancer, has seen its share price move from $1.42 on May 26 to $2.24 as of the closing bell on Monday June 8. Overall, that works out to a 58% gain over just nine trading sessions, with shareholders experiencing just a single down day in that timespan.

    So what's really behind Galena's explosion to the upside? While presentations at the American Society of Clinical Oncology, or ASCO, certainly kept the ball rolling, it's my belief that commentary from research firm Maxim Group appears to have incited the bulk of the buying.

    Wall Street and ASCO give Galena a big boost
    With Galena valued at just $1.42 per share, Maxim Group released a very bullish report on Galena, claiming the stock was a "buy" and its 2023 price target, using a combination of free cash flow for the firm, discounted EPS, and a "sum-of-the-parts modeled with a 30% discount rate," came out to $7 per share. If Galena could actually hit Maxim's target, we would be talking about a nearly 400% climb in its share price.

    Why is Maxim so excited about Galena? Primarily it has to do with the company's ability to garner partnerships for its cancer vaccine products. Maxim's note suggests cancer vaccines are catching up to CAR T-cell therapies and "fetching comparable partnership deals from big pharma." The implication here is that continued positive data from Galena in terms of its lead product, NeuVax, which is being tested in a late-stage trial known as PRESENT as an adjuvant therapy to prevent the recurrence of breast cancer in patients with low-to-moderate HER2-expression, or its burgeoning therapies such as GALE-301 for endometrial and ovarian cancer, could lend to licensing or collaboration deals that supply Ga

    Sentiment: Strong Buy

  • Reply to

    Will Close Green Today.....

    by gene4346 Jun 9, 2015 10:59 AM
    zahnd9898 zahnd9898 Jun 9, 2015 11:33 AM Flag

    NOT ONLY GREEN BUT UP!

    Sentiment: Strong Buy

  • zahnd9898 by zahnd9898 Jun 6, 2015 2:48 PM Flag

    Gale has wings and will fly!

    Sentiment: Strong Buy

RHHBY
34.13-0.72(-2.07%)3:05 PMEDT